Search Within

Matthew David Hellmann

Formats
  1. Meeting Abstract (210)
  2. Journal Article (187)
  3. Review (5)
  4. Editorial (4)
  5. Research Letter (3)
  6. Guidelines (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (412)
  2. Solid Tumor Oncology Division (412)
  3. Thoracic Oncology (412)
  4. GSK Faculty (140)
  5. Department of Pathology and Laboratory Medicine (112)
  6. Weinberg Fellows (103)

More Groups

People
  1. Hira Rizvi (97)
  2. Mark Kris (71)
  3. Jamie Chaft (68)
  4. Charles Rudin (67)
  5. Jedd Wolchok (53)
  6. Gregory Riely (49)

More People

Years
  1. 2025 (2)
  2. 2024 (7)
  3. 2023 (14)
  4. 2022 (34)
  5. 2021 (40)
  6. 2020 (55)

More Years

Publications
  1. Journal of Clinical Oncology (91)
  2. Journal of Thoracic Oncology (58)
  3. Annals of Oncology (49)
  4. Journal for ImmunoTherapy of Cancer (30)
  5. Cancer Research (24)
  6. Clinical Cancer Research (20)

More Publications

Publishers
  1. American Society of Clinical Oncology (96)
  2. Elsevier Inc. (75)
  3. American Association for Cancer Research (57)
  4. Oxford University Press (53)
  5. Biomed Central Ltd (30)
  6. Nature Publishing Group (21)

More Publishers

Results (412)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial
    Meeting Abstract

    Feils, A.; Erbe, A.; Birstler, J.; Kim, K.; Hoch, U.; Currie, S.; Nguyen, T.; Yu, D.; Siefker-Radtke, A.; Tannir, N.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227
    Meeting Abstract

    Schumann, C.; Paz-Ares, L.; Ciuleanu, T. E.; Lee, J. S.; Urban, L.; Caro, R. B.; Park, K.; Sakai, H.; Ohe, Y.; Nishio, M.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1
    Meeting Abstract

    Reck, M.; Ciuleanu, T. E.; Pluzanski, A.; Lee, J. S.; Bernabe Caro, R.; Linardou, H.; Burgers, J.; Gallardo, C.; Nishio, M.; Peters, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status
    Meeting Abstract

    Ramalingam, S. S.; Balli, D.; Ciuleanu, T. E.; Pluzanski, A.; Lee, J. S.; Schenker, M.; Caro, R. B.; Lee, K. H.; Bartolucci, R.; Audigier-Valette, C.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Phase 3 study of first-line pembrolizumab ± vibostolimab (anti-TIGIT) in patients with PD-L1‒positive metastatic NSCLC
    Meeting Abstract

    Hellmann, M. D.; Cho, B. C.; Juergens, R.; Cheng, Y.; De Castro, G. Jr; Erman, M.; Bauman, J. R.; Takahashi, T.; Schwarzenberger, P.; Zhang, P.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227
    Meeting Abstract

    Paz-Ares, L. G.; Ciuleanu, T. E.; Lee, J. S.; Urban, L.; Caro, R. B.; Park, K.; Sakai, H.; Ohe, Y.; Nishio, M.; Pluzanski, A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Association of a very high tumor mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer
    Meeting Abstract

    Ricciuti, B.; Arbour, K. C.; Alessi, J. V. M.; Mahadevan, N.; Lindsay, J.; Sinha, R.; Vokes, N. I.; Recondo, G.; Lamberti, G.; Rizvi, H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Determination of clinical benefit among patients with radiological stable disease to immune checkpoint inhibitors
    Meeting Abstract

    Luo, J.; Wu, S.; Rizvi, H.; Zhang, Q.; Egger, J. V.; Osorio, J. C.; Schoenfeld, A. J.; Plodkowski, A. J.; Ginsberg, M. S.; Gupta, A. K.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Beyond steroids: Immunosuppressants in steroid-refractory/resistant immune related adverse events
    Meeting Abstract

    Luo, J.; Beattie, J.; Fuentes, P.; Rizvi, H.; Egger, J. V.; Kern, J.; Leung, D. Y. M.; Lacouture, M. E.; Kris, M. G.; Gambarin, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Assessment of cancer-specific microbiome signature of response to immune checkpoint inhibitors
    Meeting Abstract

    Sarfaty, M.; Desjardins, C. A.; Giardina, P.; Bardhan, K.; Pandian, S.; Halley, K.; Halvorsen, E. M.; Callahan, M. K.; Postow, M. A.; Lee, C. H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save